Clinical trials
Phase 2/3 Multiple Myeloma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 6 |
| Unknown status | 6 |
| Terminated | 4 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Research UK | 2 |
| The Affiliated People's Hospital of Ningbo University | 2 |
| AbbVie | 1 |
| Austrian Forum Against Cancer | 1 |
| Azienda Ospedaliera San Giovanni Battista | 1 |
| Bristol-Myers Squibb | 1 |
| Celgene | 1 |
| Dr. med. Lars-Olof Muegge | 1 |
| Janssen Research & Development, LLC | 1 |
| Kiadis Pharma | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 30 |
| Neoplasms, Plasma Cell | 4 |
| Hematologic Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Colorectal Neoplasms | 2 |
| Erdheim-Chester Disease | 2 |
| Glioma | 2 |
| Laryngeal Neoplasms | 2 |
| Lymphoma | 2 |
| Myelodysplastic Syndromes | 2 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.